Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Castro, Javier de; González-Larriba, José-Luis; Vázquez‐Estévez, Sergio; Massutí, Bartomeu; Sánchez-Torres, J.M.; Dómine, Manuel; Garrido, Pilar; Calles, Antonio; Artal, Ángel; Collado, Rosa; García, Rogelio; Sereno, María; Majem, Margarita; Macías, J.; Juan, Óscar; Gómez-Codina, José; Hernández, Berta; Lázaro, M.; Ortega, Ana Laura; Cobo, Manuel; Trigo, José; Carcereny, Enric; Rolfo, Christian; Maciá, Sonia; Muñoz, J.; Díz, Pilar; Mendez, M.; Rosillo, F.; Paz‐Ares, Luis; Cardona, J. V.; Isla, Dolores

doi:10.1007/s12094-016-1527-8

Cited by 3 publications

(4 citation statements)

References 28 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was the first specifically designed angiogenesis inhibitor [ 3 ]. Bevacizumab has improved therapeutic effectiveness since it was introduced to chemotherapy (Bev-chemotherapy), and it has now become the normative first-line therapy for advanced NSCLC [ 4 ]. Pro-angiogenic cytokines (VEGF, angiostatin-1, and follicle inhibitor) and inflammatory cytokines (interferon (IFN), IL4, and IL17) were found to be reduced in metastatic non-small-cell lung cancer treated with the EP regimen (cisplatin plus etoposide) in combination with bevacizumab compared to the conventional EP regimen alone, demonstrating its strong anti-angiogenic effects [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells

Hanafy

Eltonouby

Salim

et al. 2023

IJMS

View full text Add to dashboard Cite

Bevacizumab (Bev) a humanized monoclonal antibody that fights vascular endothelial growth factor A (VEGF-A). It was the first specifically considered angiogenesis inhibitor and it has now become the normative first-line therapy for advanced non-small-cell lung cancer (NSCLC). In the current study, polyphenolic compounds were isolated from bee pollen (PCIBP) and encapsulated (EPCIBP) inside moieties of hybrid peptide–protein hydrogel nanoparticles in which bovine serum albumin (BSA) was combined with protamine-free sulfate and targeted with folic acid (FA). The apoptotic effects of PCIBP and its encapsulation (EPCIBP) were further investigated using A549 and MCF-7 cell lines, providing significant upregulation of Bax and caspase 3 genes and downregulation of Bcl2, HRAS, and MAPK as well. This effect was synergistically improved in combination with Bev. Our findings may contribute to the use of EPCIBP simultaneously with chemotherapy to strengthen the effectiveness and minimize the required dose.

show abstract

Section: Introductionmentioning

confidence: 99%

Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells

Hanafy

Eltonouby

Salim

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Bevacizumab is a vascular endothelial growth factor monoclonal antibody, which inhibits angiogenesis to suppress tumor growth by restricting the delivery of oxygen and nutrients to the tumor 11,12 . Since bevacizumab was added to chemotherapy (Bev‐chemotherapy), this combination enhanced treatment efficacy and has become the standard first‐line treatment for advanced NS‐NSCLC 13–21 . However, the overall survival (OS) benefit of Bev‐chemotherapy remains unsatisfactory 16,22 …”

Section: Introductionmentioning

confidence: 99%

“…11,12 Since bevacizumab was added to chemotherapy (Bev-chemotherapy), this combination enhanced treatment efficacy and has become the standard first-line treatment for advanced NS-NSCLC. [13][14][15][16][17][18][19][20][21] However, the overall survival (OS) benefit of Bev-chemotherapy remains unsatisfactory. 16,22 The introduction of immunotherapy has a howling success, changing the treatment strategy of advanced NS-NSCLC.…”

Section: Introductionmentioning

confidence: 99%

First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials

Zhai

Zhang³

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non-squamous non-small cell lung cancer (NS-NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI plus chemotherapy (ICI-chemotherapy) and bevacizumab plus chemotherapy (Bev-chemotherapy) in first-line treatment of NS-NSCLC. We identified RCTs in databases and conference abstracts presented at international conferences by Sep 1, 2021. Bayesian network metaanalysis was performed using randomized effect consistency model to estimate hazard ratio (HR) and odds ratio (OR). The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and grade ≥ 3 treatment-related adverse events (TRAEs). Fifteen RCTs (17 articles) of 6561 advanced NS-NSCLC patients receiving ICI-chemotherapy, Bev-chemotherapy, or chemotherapy at first-line were eligible for analysis. NMA results showed that first-line ICI-chemotherapy prolonged OS (HR 0.79, 0.66-0.94) in patients with advanced NS-NSCLC compared with Bev-chemotherapy, while no differences were in PFS, ORR, and grade ≥ 3 TRAEs (p > 0.05). Ranking plots suggested that ICI-chemotherapy had the most probability to offer the best OS (probability 0.993), PFS (probability 0.658), and ORR (probability 0.565), and Bev-chemotherapy had the most risks of grade ≥ 3 TRAEs (probability 0.833). Therefore, our findings showed that first-line ICI-chemotherapy was associated with better OS than Bevchemotherapy in patients with advanced NS-NSCLC, and more clinical trials are warranted to confirm these results.

show abstract

“…Primary liver cancer (PLC) is a common life-threatening tumor 1,2 with a current mortality rate close to that of lung cancer 3 . Due to the long latency period of PLC, a large number of patients reach advanced stages before diagnosis and clinical intervention [4][5][6][7] . Many patients are therefore also characterized by high recurrence and high metastasis rates [8][9][10][11] .…”

mentioning

confidence: 99%

Clinical application of thioredoxin reductase as a novel biomarker in liver cancer

Wang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such cases, but it is likewise not always able to slow or halt progression, therefore novel approaches for treatment of hepatic cancer are needed. Current research suggests that molecular tumor markers (TM) can play a crucial role for diagnosis and prognostic evaluation of malignancies, and TM such as AFP, CEA, CA19-9 have been reported in many malignant diseases. Thioredoxin reductase (TrxR), a type of anti-oxidant biomarker, has become a TM of significant interest. However, little is known about the above TM and TrxR activity in liver cancer. Therefore, this paper aimed to assess these TM with regards to diagnosis and and monitoring treatment efficacy in both primary and metastatic liver cancer. Our results showed TrxR had superior performance for discriminating between liver cancer patients and healthy controls than AFP, CEA, and CA19-9. TrxR also exhibited superior performance for assessing benefits of chemotherapy regardless if patients had PLC or MLC. Meanwhile, due to diagnostic efficiency of unresponsive chemotherapy patients, TrxR also showed a higher activity levels than other general markers in liver metastasis patients. Our results suggest that application of TrxR in combination with other tumor markers may maximize the efficiency of diagnosis and assessment of therapeutic efficiency, and provide new insights for the clinical application of TrxR as a candidate biomarker for liver cancer.

show abstract

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Abstract: Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.

Cited by 3 publications

References 28 publications

Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells

Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells

First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials

Clinical application of thioredoxin reductase as a novel biomarker in liver cancer

Contact Info

Product

Resources

About